Drug Trial Radar · NCT05101317
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
142
Actual
Start
Oct 11, 2021
Primary completion
Sep 26, 2024
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Hope Medicine (Nanjing) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Conditions
- Endometriosis
Interventions
HMI-115Drug
HMI-115 is human monoclonal antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)Time frame: Baseline, Week 12
- Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)Time frame: Baseline, Week 12
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Physicians' Research Options, LLC- Corner Canyon Clinic
Draper, Utah
Tidewater Clinical Research/TPW
Norfolk, Virginia
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Instytut Matki i Dziecka
Warsaw, Masovian Voivodeship, Poland
Specjalistyczna Poradnia Ginekologiczna Gabinet Ginekologiczny Dr med. Janusza Tomaszewskiego
Bialystok, Podlaskie Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.